



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: John Paul McGee et al.

Serial No.: 09/868,991

Art Unit: 1615

Filed

: July 26, 2001

Examiner: B.A. Fubara

For

CONTROLLED-RELEASE GALANTAMINE COMPOSITION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

October 21, 2005
(Date of Deposit)
Mary A. Appollina
(Name of applicant, assignee, or Registered Representative)
•
/Mary A. Appollina/
(Signature)
October 21, 2005
(Date of Signature)

Commissioner for Patents P.O. Box 1450 Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This copy is supplemental to the Information Disclosure Statement mailed on August 4, 2004.

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this

information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Disclosure Statement is being filed either within three months

In accordance with §1.97(b), since this Information

of the filing date of the above-identified national application
(other than a continued prosecution application under
§1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set forth
in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under §1.114, no additional
fee is required.
In accordance with §1.129(a), this Information
Disclosure Statement is being filed in connection with 🗌 the
first or _second After Final Submission, therefore:
Statement in Accordance with §1.97(e)
(attached); or
Please charge Deposit Account No. 10-
0750/ / the fee of <u>\$180.00</u> as set forth
in §1.17(p).

Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

(attached); or ☑ Please charge Deposit Account No. 10- 0750/JAB1461/MAA the fee of \$180.00 as set fort in §1.17(p). ☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p). ☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.	th
O750/JAB1461/MAA the fee of \$180.00 as set fort in \$1.17(p). In accordance with \$1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with \$1.97(e) as set forth below and the fee of \$180.00 as set forth in \$1.17(p).	th
in §1.17(p). In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of Either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Enformation Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of E180.00 as set forth in §1.17(p).	CII
In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).	
Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this information Disclosure Statement. Included are: Statement in accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).	
either a Final Action under §1.113 or a Notice of Allowance ander §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this information Disclosure Statement. Included are: Statement in accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p). Copies of each of the references listed on the	
ander §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p). Copies of each of the references listed on the	
applicant(s) hereby petition(s) for consideration of this information Disclosure Statement. Included are: Statement in accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p). Copies of each of the references listed on the	
Information Disclosure Statement. Included are: Statement in accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p). Copies of each of the references listed on the	
accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p). Copies of each of the references listed on the	
180.00 as set forth in §1.17(p). Copies of each of the references listed on the	ı
Copies of each of the references listed on the	
ittached Form PTO-1449 are enclosed herewith.	
Copies of references listed on the attached Form PTC) –
449 are enclosed herewith EXCEPT THAT:	
In view of the voluminous nature of references	
[list as appropriate], and the likelihood that	
these references are available to the Examiner,	,
copies are not enclosed herewith.	
<pre>If any of the foregoing publications are not</pre>	
available to the Examiner, Applicant will	
endeavor to supply copies at the Examiner's	
request.	
* CHACLL '	
Copies of only foreign patent documents and non-	

.


•

.

There are no listed references which are not in the \boxtimes English language. English translations are provided for JP 10-231242 and JP 9-165329. Copies of English equivalents are provided for: JP 9-295933 (EP 793 959); JP 6-507617 (WO 92/20328); JP 8-505633 (US 5,643,905); and WO 97/03987 (US 5,958,903). The relevance of those listed references which are not in the English language is as follows: Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D. Copies of the references listed on the search report(s) are included except for those previously cited in an IDS mailed Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D. Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB1461USNP/MAA. This form is submitted in triplicate. Respectfully submitted, /Mary A. Appollina/ Mary A. Appollina

Reg. No. 34,087 Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-3742 DATED: October 21, 2005



PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 3

a collection of information offices it displays	a valid OMB control flumber.
Application Number	09/868,991
Filing Date	July 26, 2001
First Named Inventor	John Paul McGee et al.
Group Art Unit	1615
Examiner Name	B.A. Fubara
Attorney Docket Number	JAB1461USNP

U.S. PATENT DOCUMENTS

Examiner Initials		U.S. Patent Document			
	Cite No. ¹	Number (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		5,151,273	Korsatko-Wabnegg et al.	09/29/1992	
		5,519,017	Klaus Opitz	05/21/1996	
		5,589,475	Snorrason	12/31/1996	
			<u> </u>		

FOREIGN PATENT DOCUMENTS


Examiner Cite Initials No.1		Foreign	Patent Documen	t	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
	Office ³	Number⁴ Kin	dCode⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T ₆	
		JP	6-507617		Burgmann Ole et al.	09-01-1994	,	
		JP	9-165329		Asahi Kasei Kogyo K.K.	06-24-1997		
		JP	10- 231242		Taiyo Yakuhin Kogyo K.K.	09-02-1998	·	
		JP	9-295933		Takeda Yakuhin Kogyo K.K.	11-18-1997		
		JP	8-505633		H.F. Altzneimittel Folschung GmbH	06-18-1996		
		wo	97/47304		Janssen Pharmaceutica N.V.	12-18-1997		
		wo	98/55148		Janssen Pharmaceutica N.V.	12-10-1998		

Examiner	Date		
Signature	Considered	•	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



- PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 3

a collection of information unless it displays	a valid Olvid Collitor national.
Application Number	09/868,991
Filing Date	July 26, 2001
First Named Inventor	John Paul McGee et al.
Group Art Unit	1615
Examiner Name	B.A. Fubara
Attorney Docket Number	JAB1461USNP

U.S. Patent Document Pages, Columns, Lines, where relevant passages or relevant figures appear Date of Publication Name of Patentee or Applicant Kind Code² of Cited Document Examiner Cite of Cited Document Initials (if known) Number mm-dd-yyyy No.1

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Initiale		Foreign	Patent Document		Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
	Cite No. ¹	Office ³	Number ⁴ Kind	lCode ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T ⁶
		wo	00/38686		Janssen Pharmaceutica N.V.	07/06/2000		
		wo	97/03987		Societe De Conseils De Recherches Et D'Applications Scientifiques	02/06/1997		
		wo	99/21561		Davis, Bonnie M.	05/06/1999		
		EP	0648771	A1	Hoechst-Rousel Pharmacueticals Incorporated	04/19/1995		
		ΕP	0653427	B1	Aventis Pharmaceuticals Inc.	05/17/1995		
		EP	0879596	A2	Snorasson, Enir Reykjavik	11/25/1998		

Examiner	Date	
Signature	Considered	

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 3 of 3

a collection of information unless it displays	a vallu Olvib cuttitui tiuttiper.
Application Number	09/868,991
Filing Date	July 26, 2001
First Named Inventor	John Paul McGee et al.
Group Art Unit	1615
Examiner Name	B.A. Fubara
Attorney Docket Number	JAB1461USNP

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Chiao, C.S.L., et al. "Sustained-Release Drug Delivery Systems." Remington: The Science and Practice of Pharmacy, Gennaro, A.R., ed. 1995, pp. 1660 & 1661	-
· :		Conte, U, et al. Press Coated Tablets For Time-Programmed Release Of Drugs, Biomaterials. 1993, VOL. 14, No. 13 Pages 1017-1023, Entire Document	
		Goodman & Gilman's The Pharmacological Basis of Therapeutics, Ninth Edition, pgs. 161-176, Chapter 8 (eds. Joel G. Hardman and Lee E. Limbird, McGraw-Hill, 1996).	
			74-7-11-11
<u>.</u>	-		
134			

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.